Gemina Laboratories LtdCanadian Securities Exchange:GLABView on OTCQB
- LAST PRICE0.4500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.4200/ 2
- Ask / Lots0.4500/ 8
- Open / Previous Close0.0000 / 0.4500
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Time | Volume | GLAB |
|---|
Jun 21, 2024
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing, from 8:35AM ET on Friday Jun 21, 2024 by Dow Jones
8:35AM ET on Friday Jun 21, 2024 by Dow Jones
Jun 20, 2024
Gemina Laboratories Commences Trading on the OTCQB Market in the United States, from 1:01PM ET on Thursday Jun 20, 2024 by Dow Jones
1:01PM ET on Thursday Jun 20, 2024 by Dow Jones
Jun 18, 2024
Life Sciences Virtual Investor Forum Agenda Announced for June 20th, from 8:35AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:35AM ET on Tuesday Jun 18, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Gemina Laboratories Ltd | 33.0M | -6.3x | --- |
Sona Nanotech Inc | 29.2M | -9.1x | --- |
Rapid Dose Therapeutics Corp | 22.0M | -5.3x | --- |
NuGen Medical Devices Inc | 20.6M | -1.9x | --- |
Enablence Technologies Inc | 29.1M | -1.9x | --- |
Cloud DX Inc | 12.1M | -1.3x | --- |
Company Information
Gemina Laboratories Ltd. is a Canada-based biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers testing platforms for a range of pathogens that affect human health and wellness. The Company operates in the in vitro diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. Its development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. It operates within a single segment, being the research, development and commercialization of in-vitro diagnostics. Its technologies include dual affinity binding mechanism, gold binding protein, cellulose binding protein and more surface binding proteins. Its products include LEGIO X, which is a COVID-19 rapid antigen test, and LEGIO XI, which is a multiplex device that can detect and distinguish between influenza types A and B with no cross reactivity. LEGIO products in development include respiratory syncytial virus and tuberculosis.
Contact Information
- Headquarters
- 3800 Westbrook Mall, Suite 142VANCOUVER, BC, Canada V6S 2L9
- Phone
- 604-763-3191
- Fax
- ---
Executives
- Chief Executive Officer, Director
- John Davies
- Chief Financial Officer, Corporate Secretary
- Michael Liggett
- Chief Technology Officer, Director
- Robert Greene
- Director
- James Tansey
- Independent Director
- Martin Cronin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $33.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 73.3M |
Gemina Laboratories Ltd does not pay a dividend. | |
Beta | --- |
EPS | $-0.07 |
Book Value | $-0.02 |
P/E Ratio | -6.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
